Niagen Bioscience, Inc. (NAGE)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 50M 100M 150M FY17: 21.2M FY18: 31.6M FY19: 46.3M FY20: 59.3M FY21: 67.4M FY22: 72M FY23: 83.6M FY24: 99.6M FY25: 129.4M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Gross Profit Annual

0 30M 60M 90M FY11: 2.9M FY11: 2.5M FY12: 2.3M FY13: 3.1M FY15: 5.3M FY16: 7.5M FY16: 10.4M FY17: 10.5M FY18: 16.1M FY19: 25.8M FY20: 35.3M FY21: 41.5M FY22: 42.8M FY23: 50.8M FY24: 61.6M FY25: 83.2M FY11 FY13 FY16 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M FY11: -2M FY11: -7.9M FY12: -11.6M FY13: -4.4M FY15: -5.2M FY16: -2.1M FY16: -2.9M FY17: -16.4M FY18: -33.2M FY19: -31.3M FY20: -19.9M FY21: -27.1M FY22: -18.6M FY23: -5.6M FY24: 7.7M FY25: 16.3M FY11 FY13 FY16 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-45M -30M -15M 0 15M 30M 45M FY11: -2.1M FY11: -7.9M FY12: -11.7M FY13: -4.4M FY15: -5.4M FY16: -2.8M FY16: -2.9M FY17: -11.4M FY18: -33.3M FY19: -32.1M FY20: -19.9M FY21: -27.1M FY22: -16.5M FY23: -4.9M FY24: 8.6M FY25: 17.4M FY11 FY13 FY16 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 20M 40M 60M FY11: 4.6M FY11: 5.6M FY12: 9.3M FY13: 7M FY15: 10M FY16: 10.4M FY16: 11.3M FY17: 10.7M FY18: 15.5M FY19: 20.5M FY20: 24M FY21: 26M FY22: 29.3M FY23: 32.8M FY24: 38M FY25: 46.2M FY11 FY13 FY16 FY17 FY19 FY21 FY23 FY25

Operating Cash Flow Annual

-27M -18M -9M 0 9M 18M 27M FY11: -2.7M FY11: -4.1M FY12: -10.1M FY13: -3.9M FY15: -2.6M FY16: -2.1M FY16: -2.9M FY17: -9.8M FY18: -20.9M FY19: -20.4M FY20: -10.6M FY21: -24.2M FY22: -15.1M FY23: 7.1M FY24: 12.1M FY25: 13.5M FY11 FY13 FY16 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-24M -16M -8M 0 8M 16M 24M FY11: -2.8M FY11: -4.2M FY12: -10.1M FY13: -4M FY15: -2.7M FY16: -2.6M FY16: -4.4M FY17: -11M FY18: -22.2M FY19: -21.2M FY11 FY11 FY12 FY13 FY15 FY16 FY16 FY17 FY18 FY19

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 35M 70M 105M FY11: 48.3M FY11: 76M FY12: 96M FY13: 100.6M FY15: 35.5M FY16: 35.9M FY16: 37.3M FY20: 61.1M FY21: 67.2M FY22: 69.7M FY23: 75M FY24: 78.1M FY25: 85.4M FY11 FY12 FY15 FY16 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.60 -0.40 -0.20 0.00 0.20 0.40 0.60 Q3 '11: -0.08 Q4 '11: -0.09 Q4 '11: -0.12 Q1 '12: -0.15 Q2 '12: -0.16 Q3 '12: -0.15 Q4 '12: -0.13 Q1 '13: -0.07 Q2 '13: -0.04 Q3 '13: -0.03 Q4 '13: -0.02 Q1 '14: -0.05 Q2 '14: -0.06 Q3 '14: -0.06 Q1 '15: -0.08 Q2 '15: -0.09 Q1 '16: -0.06 Q2 '16: -0.04 Q3 '16: -0.03 Q4 '16: -0.06 Q4 '16: -0.08 Q2 '17: -0.14 Q3 '17: -0.21 Q3 '19: -0.56 Q4 '19: -0.56 Q1 '20: -0.51 Q2 '20: -0.43 Q3 '20: -0.38 Q4 '20: -0.33 Q1 '21: -0.35 Q2 '21: -0.37 Q3 '21: -0.43 Q4 '21: -0.40 Q1 '22: -0.39 Q2 '22: -0.40 Q3 '22: -0.28 Q4 '22: -0.23 Q1 '23: -0.15 Q2 '23: -0.09 Q3 '23: -0.09 Q4 '23: -0.07 Q1 '24: -0.05 Q2 '24: -0.02 Q3 '24: 0.01 Q4 '24: 0.10 Q1 '25: 0.17 Q2 '25: 0.21 Q3 '25: 0.24 Q4 '25: 0.20 Q1 '26: 0.21 Q2 '26: 0.18 Q4 '11 Q2 '13 Q2 '15 Q3 '17 Q1 '21 Q4 '22 Q3 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.